FindTrial
Sign In

Placebo (for Dupilumab)

DRUG6 trials

Sponsors

Sanofi, Regeneron Pharmaceuticals

Conditions

AsthmaAtopic DermatitisDermatitis, AtopicNasal Polyps

Phase 2

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
CompletedNCT01312961
SanofiAsthma
Start: 2011-03-31End: 2012-10-31Updated: 2017-06-08
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
CompletedNCT01639040
Regeneron PharmaceuticalsAtopic Dermatitis
Start: 2012-07-31End: 2012-12-31Updated: 2017-10-13
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
CompletedNCT01920893
SanofiNasal Polyps
Start: 2013-08-31End: 2014-11-30Updated: 2017-06-26

Phase 3

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
CompletedNCT02260986
Regeneron PharmaceuticalsAtopic Dermatitis
Start: 2014-09-30End: 2016-10-31Updated: 2017-10-17
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
CompletedNCT02277769
Regeneron PharmaceuticalsDermatitis, Atopic
Start: 2014-11-30End: 2016-01-31Updated: 2020-06-02
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
CompletedNCT02277743
Regeneron PharmaceuticalsDermatitis, Atopic
Start: 2014-10-31End: 2016-02-29Updated: 2017-11-21

Related Papers

Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study
Advances in Therapy2026-04-18
Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment
American Journal of Clinical Dermatology2026-04-17
Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison
SKIN The Journal of Cutaneous Medicine2026-03-10
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.
2026-01-21
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
2025-11-22
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.
2025-10-16
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults
American Journal of Clinical Dermatology2025-09-24
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.
2025-09-19
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials
Advances in Therapy2025-02-192 citations
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups.
2025-02-013 citations
Dupilumab Demonstrates a Higher Likelihood of Achieving Improvements in Signs, Symptoms, and Quality of Life vs. Tralokinumab at Week 16: Results from a Bucher Indirect Treatment Comparison
SKIN The Journal of Cutaneous Medicine2024-11-18
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
Frontiers in Immunology2024-11-116 citations
686 - Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-011 citations
695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-011 citations
618 - A Bayesian network meta-analysis comparing the efficacy of dupilumab versus tralokinumab in adults with severe atopic dermatitis with inadequate response or intolerance to cyclosporin A
British Journal of Dermatology2024-08-01
675 - Dupilumab demonstrates higher likelihood of achieving improvements in signs, symptoms, and quality of life vs lebrikizumab: results from a placebo-adjusted indirect comparison analysis
British Journal of Dermatology2024-08-01
690 - SCORAD severity band threshold analysis from dupilumab clinical trials in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-01
685 - Onset and maintenance of optimal itch response in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab: post hoc analysis from LIBERTY AD CHRONOS
British Journal of Dermatology2024-08-01
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
Annals of Otology Rhinology & Laryngology2023-06-1522 citations
414 Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2023-06-011 citations

45 more papers not shown